Digital technologies are rippling through clinical research and care, promising deeper links between healthcare research and delivery. In her interview with Global Forum US Editor Ebony Dashiell-Aje (BioMarin), Digital Medicine Society CEO Jennifer Goldsack expresses concern about the lag between producing evidence that something is fit for purpose and the conversations that need to take pace with payers and HTA experts. “We don't want to demonstrate, using the best, most novel measures possible, that new therapies are making a meaningful change for patients in ways that we haven't been able to measure before but are critically important, then delay going to market because additional evidence is required by our payer colleagues because we haven't taken time to take them with us.” Jennifer served as a panelist in the Paying for Digital Health: What Evidence is Needed? discussion at DIA Global Annual Meeting 2022.